Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shin Fujimori

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Modern Rheumatology|February 12, 2015
Effects of febuxostat on serum urate level in Japanese hyperuricemia patientsTetsuya Yamamoto, Yuji Hidaka, Masaaki Inaba, et al.
Scientific Reports|August 31, 2016
Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2Hirotaka Matsuo, Tomoyuki Tsunoda, Keiko Ooyama, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|June 10, 2011
Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical studyNaoyuki Kamatani, Kamatani Naoyuki, Shin Fujimori, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|June 10, 2011
An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical studyNaoyuki Kamatani, Kamatani Naoyuki, Shin Fujimori, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|June 10, 2011
Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical studyNaoyuki Kamatani, Kamatani Naoyuki, Shin Fujimori, et al.
Annals of the Rheumatic Diseases|December 1, 2016
GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genesAkiyoshi Nakayama, Hirofumi Nakaoka, Ken Yamamoto, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Modern Rheumatology|February 12, 2015
Effects of febuxostat on serum urate level in Japanese hyperuricemia patientsTetsuya Yamamoto, Yuji Hidaka, Masaaki Inaba, et al.
Scientific Reports|August 31, 2016
Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2Hirotaka Matsuo, Tomoyuki Tsunoda, Keiko Ooyama, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|June 10, 2011
Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical studyNaoyuki Kamatani, Kamatani Naoyuki, Shin Fujimori, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|June 10, 2011
An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical studyNaoyuki Kamatani, Kamatani Naoyuki, Shin Fujimori, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|June 10, 2011
Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical studyNaoyuki Kamatani, Kamatani Naoyuki, Shin Fujimori, et al.
Annals of the Rheumatic Diseases|December 1, 2016
GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genesAkiyoshi Nakayama, Hirofumi Nakaoka, Ken Yamamoto, et al.
Pageof 4